Executive Summary
Today's literature is dominated by transcatheter aortic valve (TAVI) outcomes data, with several studies that should temper enthusiasm for indication expansion. A large Medicare analysis in JTCVS documents a more than 10-fold rise in aortic valve reinterventions after TAVI over a decade, with surgical explants now growing faster than TAVI-in-TAVI — a sobering signal as TAVI moves into younger patients. A meta-analysis of nearly 12,000 randomized patients finds no stroke benefit from routine cerebral embolic protection (CEP) during TAVI, challenging a widely adopted adjunctive technology. Meanwhile, Abbott released positive Navitor TAVI data, and Anteris Technologies (AVR.AX) surged 13.5% on continued investor enthusiasm for its DurAVR platform.
For the clinical audience: today's lead story is the Alabbadi et al. Medicare analysis, which lands at exactly the moment the field is debating lifetime management. Reinterventions after TAVI rose from 49 cases in 2013 to 505 in 2022 (APC 22.1%), with surgical explants accelerating sharply after 2017. Coupled with the new CEP meta-analysis showing no stroke reduction across 11,692 randomized patients, the day's data reinforce a recurring Valve Wire theme: as transcatheter therapy expands its footprint, the durability and adjunctive-device evidence base must catch up.
Today's Key Findings
- [NOTABLE] Medicare TAVI reintervention rates climbing rapidly — explants now growing faster than TAVI-in-TAVI (JTCVS).
- [NOTABLE] Routine cerebral embolic protection does NOT reduce stroke after TAVI in updated meta-analysis of 11,692 randomized patients (J Cardiol).
- TAVI-IE incidence 1.2% per patient-year; diabetes and balloon-expandable valves emerge as risk factors (Open Heart).
- EASIX score (LDH/creatinine/platelets) independently predicts mortality after TAVI — a low-cost risk-stratification tool.
- BMI and valve size both impact post-TAVI gradients; high-BMI patients with small valves have worst hemodynamics.
- Abbott's Navitor TAVI receives supportive new clinical data.
- Anteris (AVR.AX) +13.5% in a single session, +139% over six months.
Aortic Valve (TAVR/TAVI)
[NOTABLE] The reintervention curve is bending the wrong way. Alabbadi and colleagues queried Medicare claims for 324,701 TAVI recipients between 2013 and 2022 and identified 2,387 reinterventions — 61.3% TAVI-in-TAVI and 38.7% surgical explants. The raw number of reinterventions exploded from 49 per year to 505 per year (APC 22.1%, p<0.001). After an initial decline (2013-2019), the TAVI-in-TAVI rate accelerated sharply (APC +35.2% from 2019-2022), and surgical explant rates have risen steadily since 2017 (APC +18.3%). Thirty-day mortality after reintervention was 8.7% and one-year mortality 18.7%, although adjusted mortality and HF hospitalization rates have improved over time. Editorial context: the ESC 2025 guidelines elevated TAVI to first-line in patients ≥70 with tricuspid anatomy, and the ACC/AHA framework already extends TAVI to many 65-80 year-olds via shared decision-making. These data — particularly the rising explant trajectory — underscore why "lifetime management" planning at the index procedure is now a mandatory ESC consideration. Explant carries 12-17% mortality in contemporary series; the Medicare 8.7% 30-day figure here likely reflects survivor bias and selective referral. The Badhwar/Mehaffey critique of indication creep finds clear support here.
[NOTABLE] Cerebral embolic protection — time to stop using it routinely? Kholeif et al. aggregated 8 RCTs and 11,692 patients comparing CEP versus no CEP during TAVI. There was no significant reduction in overall stroke at 2-5 days (RR 0.95) or 30 days (RR 0.93), no benefit for disabling stroke (RR 0.70 at 2-5 days, RR 1.18 at 30 days — neither significant), and no improvement in bleeding, vascular, or AKI endpoints. Trial sequential analysis confirmed the conclusiveness. This is the strongest signal yet that routine CEP — adopted broadly despite mixed prior data and the negative PROTECTED TAVR — adds cost without measurable population-level benefit. Selected high-risk anatomy may still benefit, but reflexive use is hard to justify. Notably, the new CAPTURE-2 trial (EmStop vs. Sentinel) continues to enroll despite the unsettled value proposition.
TAVI endocarditis — diabetes as the dominant driver. Jordal et al. conducted a case-control study (71 TAVI-IE cases, 213 matched controls) at Haukeland University Hospital. Incidence was 1.2% per patient-year, with diabetes mellitus as the only independent predictor (SHR 2.08, 95% CI 1.19-3.65). Balloon-expandable valves were over-represented in TAVI-IE (28% vs. 13%, p=0.003), and Enterococcus faecalis was the dominant pathogen (30%). All-cause mortality doubled in patients with TAVI-IE (HR 2.13). A separate systematic review by Khasnavis et al. describes the underrecognized entity of isolated native valve endocarditis after TAVI — affecting 18.4% of post-TAVI endocarditis cases, often involving the mitral valve, and more common with the CoreValve platform (OR 1.55).
BMI, valve size, and hemodynamics. Koontz et al. (n=180) found that high-BMI patients receiving small balloon-expandable valves (20/23 mm) had significantly higher mean gradients at 30 days than low-BMI patients receiving larger valves. In low-BMI patients, valve size mattered little. The data argue for aggressive annular sizing in obese patients and raise the question of whether pre-TAVI weight optimization deserves study.
Risk stratification gets simpler. Biyikli et al. (n=742) demonstrated that the EASIX score — calculated from LDH, creatinine, and platelet count — independently predicts both in-hospital (OR 1.29) and overall mortality (HR 1.21 per unit) after TAVI, with meaningful reclassification beyond age, sex, LVEF, and BNP. One-year survival was 87.4%, 93.4%, and 78.1% across tertiles. A pragmatic addition to the pre-TAVI workup.
Conduction recovery — encouraging but cautionary. Krányák et al. followed 33 patients who received a pacemaker after TAVI; half showed conduction recovery at a mean 1.7-year follow-up. Wider baseline QRS predicted persistent AV block. Clinically meaningful for the ~10% of TAVI patients who get a PPM — many may not be truly dependent.
Navitor study release. MassDevice reports favorable new data backing Abbott's Navitor self-expanding TAVI system. Navitor remains a distant third in the US market behind Edwards SAPIEN and Medtronic Evolut, but Abbott has been steadily building its structural heart presence with this platform alongside TriClip and MitraClip.
Surgical vs. Transcatheter Comparisons
The day's two most consequential papers — the Medicare reintervention analysis and the CEP meta-analysis — both point toward a more circumspect view of TAVI expansion. The reintervention data are particularly important context for ongoing trials enrolling younger and lower-risk populations (Evolut EXPAND TAVR II, ALLIANCE SAPIEN X4, the 4,000-patient TAVI-vs-SAVR comparison NCT05261204). Critics including Kaul, Miller, and Chikwe have long argued that lifetime durability data lag indication expansion; the rising explant trajectory is the first quantitative evidence that the "second valve problem" is arriving in earnest.
The ARTIST trial (Trilogy vs. SAVR for aortic regurgitation, JenaValve, n=1,016) is enrolling and remains the highest-stakes pure transcatheter-vs-surgical contest currently active. Both ACC/AHA and ESC guidelines list TAVI for AR only as Class IIb — ARTIST has the potential to either expand or shut the door on that indication.
Device & Technology
A novel in-silico pace-mapping platform (Campos et al., Heart Rhythm) validated patient-specific computational models to localize VT origin sites within ~8 mm of clinical ground truth across 18 structural heart patients. Although not a valve study per se, the technology has obvious implications for post-procedural arrhythmia management — particularly given the ongoing PPM and conduction issues after TAVI.
A case report (Sanchez et al.) highlights successful TAVI using a cobalt-chromium frame in a patient with severe nickel, palladium, and iridium hypersensitivity — a niche but increasingly relevant consideration as metal allergy testing becomes more common in pre-procedural evaluation.
Regulatory & Policy
No formal regulatory actions reported today. The Navitor data release may inform future label expansion discussions for Abbott's TAVI platform, but no FDA action has been announced.
Industry & Market
Abbott's Navitor data release continues the company's structural heart momentum across aortic, mitral (MitraClip), and tricuspid (TriClip) positions — though the stock has been pressured by broader concerns this year (-30% over six months). Anteris Technologies (AVR.AX) had a dramatic +13.5% day, capping a +139% six-month run as investors continue to bid up its differentiated DurAVR single-piece tissue valve platform ahead of pivotal data.
Financial Analysis
The structural heart equity narrative remains bifurcated. The large-cap incumbents — Edwards, Medtronic, Abbott, Boston Scientific — are all trading well below their 6-month highs, with Medtronic (-21.6%), Abbott (-30.2%), and Boston Scientific (-41.5%) absorbing macro and tariff-related pressure rather than valve-specific bad news. Edwards has been notably more resilient (-2.5%), supported by SAPIEN's franchise dominance, ongoing EARLY TAVR-driven asymptomatic AS expansion, and the EVOQUE tricuspid replacement system gaining real-world traction (TVT Registry data showed 98.4% implant success, 3.1% 30-day mortality).
Anteris remains the clear small-cap outlier, with a market cap of ~$1.2B and a single covering analyst — a setup characteristic of pre-pivotal structural heart names. The day's Medicare reintervention data are a double-edged sword for the entire sector: they validate a growing reintervention market (favoring valve makers with TAV-in-TAV-friendly designs and explant-capable surgical alternatives) while also raising durability questions that could ultimately slow indication expansion in the lower-risk, younger patient cohorts where growth is expected.
The CEP meta-analysis is more directly negative for Boston Scientific's Sentinel device, although routine use was already under pressure after PROTECTED TAVR. EmStop's CAPTURE-2 trial (n=663) continues to enroll despite the unfavorable evidence backdrop.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Price: $82.97 (+0.99%); 6-month change -2.54%
- Market cap: $47.8B | P/E: 44.85 trailing, 24.67 forward | Beta: 0.87
- 52-week range: $72.30 - $87.89
- Analyst target: $97.15 (range $84-$110, 27 analysts) | Rec: Buy
- Next earnings: July 23, 2026 (EPS est. $0.74, Rev est. $1.70B)
The most resilient name in the group. EVOQUE TVT Registry data and continued SAPIEN franchise dominance underpin the relative outperformance. PASCAL CLASP TR data flow remains a 2026 catalyst.
Medtronic (MDT)
- Price: $78.15 (-0.55%); 6-month change -21.57%
- Market cap: $100.3B | P/E: 21.83 trailing, 12.9 forward | Beta: 0.63
- 52-week range: $74.40 - $106.33
- Analyst target: $108.00 (range $90-$121, 25 analysts) | Rec: Buy
- Next earnings: June 3, 2026 (EPS est. $1.56, Rev est. $9.61B)
Trading near 52-week lows. Evolut EXPAND TAVR II readout and Intrepid TMVR enrollment progress remain the structural heart catalysts. Forward P/E of 12.9 reflects deep pessimism.
Abbott (ABT)
- Price: $88.38 (-0.50%); 6-month change -30.23%
- Market cap: $153.9B | P/E: 24.76 trailing, 14.57 forward | Beta: 0.65
- 52-week range: $81.97 - $139.06
- Analyst target: $118.64 (range $92-$143, 25 analysts) | Rec: Buy
- Next earnings: July 16, 2026 (EPS est. $1.28, Rev est. $12.53B)
Today's positive Navitor data are a modest tailwind for the structural heart franchise (MitraClip, TriClip, Navitor, Tendyne). bRIGHT real-world TriClip data continue to read out positively. The broader stock weakness is macro/portfolio-driven rather than valve-specific.
Boston Scientific (BSX)
- Price: $56.67 (-0.25%); 6-month change -41.50%
- Market cap: $84.2B | P/E: 23.71 trailing, 15.06 forward | Beta: 0.62
- 52-week range: $52.52 - $109.50
- Analyst target: $83.47 (range $60-$106, 32 analysts) | Rec: Strong Buy
- Next earnings: July 29, 2026 (EPS est. $0.83, Rev est. $5.40B)
The worst structural heart performer in the cohort. Sentinel CEP device faces increased headwinds from today's meta-analysis. ACURATE neo2 (post-trial outcomes), Watchman, and Farapulse remain the broader growth drivers.
Anteris Technologies (AVR.AX)
- Price: A$12.54 (+13.48%); 6-month change +138.86%
- Market cap: $1.2B | Forward P/E: -5.75 | Beta: 0.59
- 52-week range: A$4.68 - A$12.70
- Analyst target: A$13.00 (1 analyst)
Speculative but momentum-driven. DurAVR's single-piece tissue valve concept attracts investors looking for differentiation against incumbent leaflet platforms. Pivotal trial timing remains the key swing factor.
Market outlook: The sector's defensive low-beta characteristics (all major names <0.9) have not insulated investors from a punishing six months, with the exception of EW. Today's negative data on CEP and the rising explant signal in Medicare are reminders that structural heart's growth narrative is no longer one-way; the field is moving into a phase where evidence-based skepticism may finally moderate procedural enthusiasm. Anteris remains the speculative outlier on a fundamentally different bet — that next-generation tissue engineering can solve the durability problem the incumbents have not.
JenaValve Technology, J Valve Technology, and Meril Life Sciences are private and not included in the equity analysis.
Clinical Trial Updates
Aortic
- NCT05149755 — Evolut EXPAND TAVR II Pivotal: Active, not recruiting | n=650 | Medtronic. Key indication-expansion trial in moderate AS.
- [LANDMARK] NCT02701283 — Evolut Low Risk: Active, not recruiting | n=2,223 | Medtronic. Long-term follow-up — critical for durability discussion in light of today's Medicare reintervention data.
- NCT05172960 — ALLIANCE SAPIEN X4: Active, not recruiting | n=1,234 | Edwards. Next-generation balloon-expandable platform.
- NCT06608823 — ARTIST (Trilogy vs. SAVR for AR): Recruiting | n=1,016 | JenaValve. The pivotal AR trial; AR remains Class IIb for TAVI in both guidelines.
- NCT05261204 — TAVI vs. SAVR: Enrolling by invitation | n=4,000 | Centre Cardiologique du Nord. Large head-to-head comparison.
- NCT07276711 — CAPTURE-2 (EmStop vs. Sentinel CEP): Recruiting | n=663. Continues despite today's negative routine-CEP meta-analysis.
- NCT06168370 — CT-Guided Antithrombotic Therapy post-TAVI: Recruiting | n=2,500.
- NCT05774691 — POPular ACE TAVI (Routine vs. Selective Protamine): Completed | n=1,000. Results awaited.
- NCT05758662 — POPular PET TAVI (Subclinical Leaflet Thrombosis): Recruiting | n=180.
- NCT03728049 — Von Willebrand Factor POC Testing for TAVI: Recruiting | n=944.
- NCT07596394 — Pavia TAVI Registry: Recruiting | n=500.
Mitral Repair
- [LANDMARK] NCT04198870 — REPAIR-MR (MitraClip vs. surgery for primary MR): Active, not recruiting | n=500 | Abbott. Could expand TEER into surgical-grade primary MR territory if positive.
- [LANDMARK] NCT05051033 — PRIMARY (TEER vs. medical therapy for secondary MR): Recruiting | n=450.
- [LANDMARK] NCT03706833 — COAPT (long-term follow-up): Active, not recruiting | n=1,247. The trial that elevated TEER to ESC Class I.
- NCT05090540 — TEER vs. Surgery for Secondary MR: Enrolling by invitation | n=600.
- NCT07301151 — PASCAL Feasibility Study: Not yet recruiting | n=120.
Mitral Replacement
- NCT03242642 — APOLLO (Intrepid TMVR): Recruiting | n=1,056 | Medtronic.
- NCT06414265 — SATURN TMVR (EU): Recruiting | n=30 | InnovHeart.
- NCT07130994 — CASSINI-US (SATURN TMVR US): Not yet recruiting | n=15.
Tricuspid Repair
- [LANDMARK] NCT03904147 — TRILUMINATE Pivotal (TriClip): Active, not recruiting | n=572 | Abbott. The trial that drove ESC Class IIa transcatheter tricuspid recommendation.
- [LANDMARK] NCT04097145 — CLASP II TR (PASCAL): Recruiting | n=1,270 | Edwards.
- NCT04483089 — bRIGHT (TriClip real-world): Active, not recruiting | n=511 | Abbott.
Tricuspid Replacement
- [LANDMARK] NCT04482062 — TRISCEND II (EVOQUE): Active, not recruiting | n=864 | Edwards. Two-year data now informing real-world TVT Registry experience.
- NCT06611579 — MonarQ (inQB8 TTVR): Recruiting | n=50.
Social & Conference Highlights
No major conference activity today. EuroPCR coverage and TVT 2026 abstracts will increasingly drive valve discussion in coming weeks; expect community discussion of the Alabbadi Medicare reintervention paper and the CEP meta-analysis to accelerate on cardio-Twitter and at upcoming Heart Team panels.
Looking ahead: Two complementary signals today — rising TAVI explants and no routine benefit from cerebral embolic protection — should anchor the conversation as the field debates how aggressively to push TAVI into younger and asymptomatic populations. Watch for editorial responses in JACC and EHJ, and for whether the next ACC/AHA update incorporates these lifetime-management realities.
— E. Nolan Beckett, The Valve Wire